Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul-Aug;35(4):2313-2319.
doi: 10.21873/invivo.12505.

Non-melanoma Skin Cancer Treated by Contact High-dose-rate Radiotherapy (Brachytherapy): A Mono-institutional Series and Literature Review

Luca Tagliaferri  1 , Francesco Giuseppe Ciardo  2 , Bruno Fionda  3 , Calogero Casà  1 , Alessandro DI Stefani  4   5 , Valentina Lancellotta  1 , Elisa Placidi  1 , Gabriella Macchia  6 , Nikola Dino Capocchiano  1 , Alessio Giuseppe Morganti  7   8 , György Kovács  9 , Francesco Bussu  10   11 , Ketty Peris  4   5 , Vincenzo Valentini  1   2
Affiliations
Review

Non-melanoma Skin Cancer Treated by Contact High-dose-rate Radiotherapy (Brachytherapy): A Mono-institutional Series and Literature Review

Luca Tagliaferri et al. In Vivo. 2021 Jul-Aug.

Abstract

Background/aim: Non-melanoma skin cancers (NMSC) are the most common neoplasms worldwide and their incidence has been proven to increase in recent years and their treatment should aim at cancer cure as well as cosmetic and functional results. The aim of the study was to report the results of our mono-institutional series of high-dose-rate radiotherapy (cHDR-RT) in NMSC, based on a homogenous technique and two different treatment schedules.

Patients and methods: All patients affected by NMSC who were consecutively evaluated and treated at our Interventional Oncology Center from October 2018 to August 2020, were included. Patients underwent cHDR-RT using flap applicators and remotely afterloaded Ir-192 sources.

Results: Overall, 51 patients were treated for a total of 67 lesions. Local control (LC) and disease-specific survival (DSS) were 94.0% and 100%, respectively. Grade 1, grade 2, grade 3 and grade 4 acute toxicity rates were 24.6%, 3.5%, 3.5%, and 0.0%, respectively. The cosmetic results were graded as excellent/good, fair, and poor in 73.7%, 19.3%, and 7.0%.

Conclusion: cHDR-RT of NMSC is an effective alternative to surgery due to excellent outcomes both in terms of local control and aesthetic results especially in the face.

Keywords: Non-melanoma skin cancer; brachytherapy; radiation therapy.; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Kaplan-Meier curves. A. Actuarial local control. B. Actuarial overall survival and disease-specific survival.
See this image and copyright information in PMC

References

    1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069–1080. doi: 10.1111/j.1365-2133.2012.10830.x. - DOI - PubMed
    1. Cives M, Mannavola F, Lospalluti L, Sergi MC, Cazzato G, Filoni E, Cavallo F, Giudice G, Stucci LS, Porta C, Tucci M. Non-melanoma skin cancers: Biological and clinical features. Int J Mol Sci. 2020;21(15):5394. doi: 10.3390/ijms21155394. - DOI - PMC - PubMed
    1. Tagliaferri L, Lancellotta V, Fionda B, Panza G, Cornacchione P, Colloca G, Azario L, Mattiucci GC, Gambacorta MA, Valentini V. Subungual squamous cell carcinoma of the thumb treated by “function sparing approach” using contact radiotherapy (brachytherapy) Turk J Oncol. 2019;34:283–286. doi: 10.3390/ijms21155394. - DOI
    1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Squamous cell skin cancer. Version 1. 2021-February 5, 2021 ed. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465... accessed on April 17 2021] - PubMed
    1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Basal cell skin cancer. Version 2. 2021-February 25, 2021 ed. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416... accessed on April 17 2021] - PubMed